Blue Chip, an independent, full-service global marketing agency, announced the launch of Blue Chip Patient Recruitment (BCPR), a division dedicated to serving pharmaceutical and biotech clients with clinical trial recruitment marketing. BCPR's first client is BioSante Pharmaceuticals, Inc.
"We are pleased to launch the new division with an integrated program for BioSante," said Blue Chip Chairman and CEO Stanton Kawer. "Our track record to date has included conducting nearly 600 clinical trials with a 90 percent success rate, making the launch of Blue Chip Patient Recruitment a natural evolution of our business."
BCPR uses a scientific and tested approach to clinical trial marketing that combines proprietary predictive modeling tools with original patient acquisition strategies and continuous evaluation. It leverages Blue Chip's ability to develop the appropriate media and buying mix with firsthand experience in helping physicians effectively manage the site recruitment process to deliver maximum results.
BioSante Pharmaceuticals is an Illinois-based pharmaceutical company focused on developing products for female sexual health and oncology. BCPR is conducting a centrally-managed patient recruitment marketing program for its Phase 3 clinical trial called the Bloom Study. It investigates the safety and efficacy of LibiGel®, an investigational medication for the treatment of Hypoactive Sexual Desire Disorder (HSDD).
"Blue Chip Patient Recruitment is executing a comprehensive and creative marketing campaign, including a web-based solution that is critical to the success of the overall program," said Bill Milling, Senior Director of Operations, BioSante Pharmaceuticals.
At the outset, the Bloom Study presented several unique patient recruitment challenges: a very narrow patient population, multiple study protocols and a patient population difficult to reach through mass media. BCPR overcame these challenges by focusing on cost-effective, results-oriented strategies including a digital marketing component. The digital program incorporated behavioral and contextual retargeting strategies and tracking and analysis of thousands of pre-qualified leads.
In addition to BioSante Pharmaceuticals, Blue Chip has developed patient recruitment programs for Novartis, Johnson & Johnson, Pfizer, AstraZeneca, Abbott and Takeda, among others.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.